MiR-122 radiosensitize hepatocellular carcinoma cells by suppressing cyclin G1

References

• Amr KS, Elmawgoud Atia HA, Elazeem Elbnhawy RA, Ezzat WM. 2017. Early diagnostic evaluation of miR-122 and miR-224 as biomarkers for hepatocellular carcinoma. Genes Dis. 4(4):215–221.
   PubMed Web of Science ®Google Scholar
• Baumann BC, Wei J, Plastaras JP, Lukens JN, Damjanov N, Hoteit M, Hsu C, Levine M, Mondschein J, Nadolski G, et al. 2018. Stereotactic body radiation therapy (SBRT) for hepatocellular carcinoma: high rates of local control with low toxicity. Am J Clin Oncol. 41(11):1118–1124.
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. 2018. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Cao F, Yin LX. 2019. miR-122 enhances sensitivity of hepatocellular carcinoma to oxaliplatin via inhibiting MDR1 by targeting Wnt/β-catenin pathway. Exp Mol Pathol. 106:34–43.
   PubMed Web of Science ®Google Scholar
• Chang J, Nicolas E, Marks D, Sander C, Lerro A, Buendia MA, Xu C, Mason WS, Moloshok T, Bort R, et al. 2004. miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol. 1(2):106–113.
   PubMedGoogle Scholar
• Chawla SP, Bruckner H, Morse MA, Assudani N, Hall FL, Gordon EM. 2019. A phase I-II study using rexin-G tumor-targeted retrovector encoding a dominant-negative cyclin G1 inhibitor for advanced pancreatic cancer. Mol Ther Oncolytics. 12:56–67.
   PubMed Web of Science ®Google Scholar
• Choi SH, Seong J. 2018. Strategic application of radiotherapy for hepatocellular carcinoma. Clin Mol Hepatol. 24(2):114–134.
   PubMed Web of Science ®Google Scholar
• Coulouarn C, Factor VM, Andersen JB, Durkin ME, Thorgeirsson SS. 2009. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene. 28(40):3526–3536.
   PubMed Web of Science ®Google Scholar
• Ding FN, Gao BH, Wu X, Gong CW, Wang WQ, Zhang SM. 2019. miR-122-5p modulates the radiosensitivity of cervical cancer cells by regulating cell division cycle 25A (CDC25A). FEBS Open Bio. 9(11):1869–1879.
   PubMed Web of Science ®Google Scholar
• Fornari F, Gramantieri L, Giovannini C, Veronese A, Ferracin M, Sabbioni S, Calin GA, Grazi GL, Croce CM, Tavolari S, et al. 2009. MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res. 69(14):5761–5767.
   PubMed Web of Science ®Google Scholar
• Forner A, Da Fonseca LG, Díaz-González Á, Sanduzzi-Zamparelli M, Reig M, Bruix J. 2019. Controversies in the management of hepatocellular carcinoma. JHEP Rep. 1(1):17–29.
   PubMedGoogle Scholar
• Forner A, Reig M, Bruix J. 2018. Hepatocellular carcinoma. Lancet. 391(10127):1301–1314.
   PubMed Web of Science ®Google Scholar
• Ge Y, Tu W, Li J, Chen X, Chen Y, Xu Y, Xu Y, Wang Y, Liu Y. 2020. MiR-122-5p increases radiosensitivity and aggravates radiation-induced rectal injury through CCAR1. Toxicol Appl Pharmacol. 399:115054.
   PubMed Web of Science ®Google Scholar
• Gramantieri L, Ferracin M, Fornari F, Veronese A, Sabbioni S, Liu CG, Calin GA, Giovannini C, Ferrazzi E, Grazi GL, et al. 2007. Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res. 67(13):6092–6099.
   PubMed Web of Science ®Google Scholar
• Huang P, Yu G, Kapp DS, Bian XF, Ma CS, Li HS, Chen JH, Liang YQ, Zhang Y, Qin SH, Xie YQ, et al. 2018. Cumulative dose of radiation therapy of hepatocellular carcinoma patients and its deterministic relation to radiation-induced liver disease. Med Dosim. 43(3):258–266.
   PubMed Web of Science ®Google Scholar
• Jin Y, Wang J, Han J, Luo D, Sun Z. 2017. MiR-122 inhibits epithelial-mesenchymal transition in hepatocellular carcinoma by targeting Snail1 and Snail2 and suppressing WNT/β-cadherin signaling pathway. Exp Cell Res. 360(2):210–217.
   PubMed Web of Science ®Google Scholar
• Kimura SH, Ikawa M, Ito A, Okabe M, Nojima H. 2001. Cyclin G1 is involved in G2/M arrest in response to DNA damage and in growth control after damage recovery. Oncogene. 20(25):3290–3300.
   PubMed Web of Science ®Google Scholar
• Kutay H, Bai S, Datta J, Motiwala T, Pogribny I, Frankel W, Jacob ST, Ghoshal K. 2006. Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J Cell Biochem. 99(3):671–678.
   PubMed Web of Science ®Google Scholar
• Lee IJ, Seong J. 2011. Radiosensitizers in hepatocellular carcinoma. Semin Radiat Oncol. 21(4):303–311.
   PubMed Web of Science ®Google Scholar
• Ma D, Jia H, Qin M, Dai W, Wang T, Liang E, Dong G, Wang Z, Zhang Z, Feng F. 2015. MiR-122 induces radiosensitization in non-small cell lung cancer cell line. Int J Mol Sci. 16(9):22137–22150.
   PubMed Web of Science ®Google Scholar
• Ma J, Li T, Han X, Yuan H. 2018. Knockdown of LncRNA ANRIL suppresses cell proliferation, metastasis, and invasion via regulating miR-122-5p expression in hepatocellular carcinoma. J Cancer Res Clin Oncol. 144(2):205–214.
   PubMed Web of Science ®Google Scholar
• Mohkam K, Golse N, Bonal M, Ledochowski S, Rode A, Selmaji IE, Merle P, Ducerf C, Mornex F, Mabrut JY. 2016. Conformal radiotherapy as a bridge to liver transplantation for hepatocellular carcinoma: is it safe? Future Oncol. 12(13):1577–1586.
   PubMed Web of Science ®Google Scholar
• Nakao K, Miyaaki H, Ichikawa T. 2014. Antitumor function of microRNA-122 against hepatocellular carcinoma. J Gastroenterol. 49(4):589–593.
   PubMed Web of Science ®Google Scholar
• Park S, Yoon WS, Rim CH. 2020. Indications of external radiotherapy for hepatocellular carcinoma from updated clinical guidelines: Diverse global viewpoints. World J Gastroenterol. 26(4):393–403.
   PubMed Web of Science ®Google Scholar
• Qi P, Cheng SQ, Wang H, Li N, Chen YF, Gao CF. 2011. Serum microRNAs as biomarkers for hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection. PLoS One. 6(12):e28486.
   PubMed Web of Science ®Google Scholar
• Skotzko M, Wu L, Anderson WF, Gordon EM, Hall FL. 1995. Retroviral vector-mediated gene transfer of antisense cyclin G1 (CYCG1) inhibits proliferation of human osteogenic sarcoma cells. Cancer Res. 55(23):5493–5498.
   PubMed Web of Science ®Google Scholar
• Song JH, Jeong BK, Choi HS, Jeong H, Lee YH, Kim HJ, Kim TH, Jung WT, Lee OJ, Jang HS, et al. 2017. Defining radiation-induced hepatic toxicity in hepatocellular carcinoma patients treated with stereotactic body radiotherapy. J Cancer. 8(19):4155–4161.
   PubMed Web of Science ®Google Scholar
• Thakral S, Ghoshal K. 2015. miR-122 is a unique molecule with great potential in diagnosis, prognosis of liver disease, and therapy both as miRNA mimic and antimir. Curr Gene Ther. 15(2):142–150.
   PubMed Web of Science ®Google Scholar
• Wang S, Zheng W, Ji A, Zhang D, Zhou M. 2019. Overexpressed miR-122-5p promotes cell viability, proliferation, migration and glycolysis of renal cancer by negatively regulating PKM2. Cancer Manag Res. 11:9701–9713.
   PubMed Web of Science ®Google Scholar
• Wu CH, Chen CY, Yeh CT, Lin KH. 2020. Radiosensitization of hepatocellular carcinoma through targeting radio-associated microRNA. IJMS. 21(5):1859.
   Web of Science ®Google Scholar
• Xu G, Bu S, Ge WX. 2021. H. Silencing the expression of cyclin g1 enhances the radiosensitivity of hepatocellular carcinoma in vitro and in vivo by inducing apoptosis. Radiat Res. 195(4):378–384. DOI:https://doi.org/10.1667/RADE-20-00180.1.
   Google Scholar
• Xu Z, Liu G, Zhang M, Zhang Z, Jia Y, Peng L, Zhu Y, Hu J, Huang R, Sun X. 2018. miR-122-5p inhibits the proliferation, invasion and growth of bile duct carcinoma cells by targeting ALDOA. Cell Physiol Biochem. 48(6):2596–2606.
   PubMedGoogle Scholar
• Yan J, Jiang JY, Meng XN, Xiu YL, Zong ZH. 2016. MiR-23b targets cyclin G1 and suppresses ovarian cancer tumorigenesis and progression. J Exp Clin Cancer Res. 35:31.
   PubMed Web of Science ®Google Scholar